1. Pink Sheet
  2. >>Agency Leadership
  3. >>US FDA

Generic Labeling Problems Targeted In US FDA Budget Request

 
• By Derrick Gingery

Agency seeks legislative authority to update outdated generic drug labels when the reference product has been withdrawn.

Generics

The US FDA has proposed settling issues with outdated generic drugs labels through its fiscal year 2020 budget request, asking for authority to change them after they become ostensibly frozen.

The agency wants the ability to update human and animal generic drug labels when the "labeling becomes outdated, including to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

US FDA ANDA Priority Pilot ‘Practically Unusable’ Without Tweaks, AAM CEO Says

 
• By Sarah Karlin-Smith

Association for Accessible Medicines CEO John Murphy told the Pink Sheet that the FDA may need to consider phasing in the requirements for the new ANDA priority voucher incentive program if it wants sponsors to apply in the near-term.

US FDA Begins ‘Competitive Search’ For New Drugs Center Director

 
• By Derrick Gingery and Sarah Karlin-Smith

The FDA deputy commissioner emailed staff asking anyone interested in the position to send her their curriculum vitae, an unusual method for finding candidates for a high-level position.

Pink Sheet Podcast: Examining George Tidmarsh’s Departure As Head Of US FDA’s Drug Center

 
• By Derrick Gingery, Sarah Karlin-Smith, Sue Sutter, and Nielsen Hobbs

Pink Sheet reporter and editors explain Tidmarsh’s abrupt resignation as the FDA’s chief drug regulator and the potential impact on the already reeling agency.

FDA Office of New Drugs Director Mary Thanh Hai Not Interested In CDER Director Job

 
• By Sue Sutter

The 27-year agency veteran has not been formally approached about filling the vacancy created by George Tidmarsh’s resignation, but also is not interested in the position, the Pink Sheet has learned.

More from Agency Leadership

US FDA’s Richard Pazdur Says ‘No’ To CDER Director’s Spot

 
• By Sue Sutter, Sarah Karlin-Smith, and Derrick Gingery

Center for Drug Evaluation and Research staff continue to wait for a replacement for George Tidmarsh, who resigned Nov. 2 after less than four months in the position.

Australia’s Tony Lawler Takes Charge of International Regulatory Coalition

 
• By Neena Brizmohun

Lawler, who leads the Therapeutic Goods Administration, has replaced the European Medicines Agency’s Emer Cooke as chair of the International Coalition of Medicines Regulatory Authorities.

Tidmarsh Creates More Instability And Uncertainty For US FDA, Industry

 
• By Sarah Karlin-Smith

The issues surrounding the FDA's Center for Drug Evaluation and Research director are raising new concerns about more career staff attrition, which likely will negatively impact the drug industry.